PTSD research entered a critical phase in 2024 when the FDA rejected MDMA-assisted therapy for PTSD despite promising Phase 3 data, citing methodological concerns. The decision reshaped psychedelic research broadly and renewed focus on alternative PTSD approaches. Active research includes other psychedelic-assisted therapies, novel pharmacological mechanisms, and refined evidence-based therapies. For patients with PTSD, particularly treatment-resistant disease, clinical trials for ptsd remain an important option. This guide covers how to find PTSD trials, active research areas, eligibility considerations, and resources.
Categories of PTSD trials
Active PTSD trials in 2026 include:
Psychedelic-assisted therapy: Trials continuing to test psilocybin, MDMA (with refined methodology following the FDA rejection), and other psychedelics for PTSD.
Novel pharmacological mechanisms: Beyond SSRIs, mechanisms targeting fear extinction, memory reconsolidation, and stress response.
Cognitive processing therapy and prolonged exposure refinements: Trials optimizing evidence-based psychotherapies.
Cannabinoids: CBD and other cannabinoid trials specifically for PTSD.
Stellate ganglion block: Anesthetic injection that has shown some efficacy for PTSD; trials refining technique and patient selection.
Digital therapeutics: VR-based exposure therapy, app-based interventions.
Veteran-specific research: VA-led trials for combat-related PTSD.
Where to find PTSD trials
Resources:
- ClinicalTrials.gov
- National Center for PTSD (VA)
- Major academic psychiatry and psychology programs
- VA medical centers (for veterans)
- NIMH research initiatives
Typical eligibility for PTSD trials
Common inclusion criteria:
- PTSD diagnosis meeting DSM-5 criteria
- Specific symptom severity (CAPS-5 score in range)
- Adequate trauma documentation
- Capacity to engage in trauma-focused work (for therapy trials)
Common exclusion criteria:
- Active suicidality
- Active psychosis
- Severe substance use disorder
- Bipolar disorder (for some trials)
- Pregnancy
Frequently Asked Questions
Are MDMA-assisted therapy trials still active?
Yes, with refined methodology following the 2024 FDA rejection. Research continues toward potential future approval.
What is psilocybin therapy for PTSD?
Psilocybin (psychedelic mushroom compound) combined with therapeutic support sessions. Phase 2 trials are testing this approach.
Are PTSD trials available for veterans?
Yes, with extensive VA-led research programs. Veterans should ask their VA providers about trial options.
Can I participate in PTSD trials with depression comorbidity?
Often yes, given the high comorbidity. Specific trials test patients with comorbid PTSD and depression.
What is stellate ganglion block?
An anesthetic injection in the neck that has shown some efficacy for PTSD symptoms in some studies. Trials continue to refine technique and identify which patients benefit.
The bottom line on PTSD trials
PTSD research continues actively despite the 2024 MDMA setback. Multiple novel approaches in development for treatment-resistant PTSD. VA and major academic centers provide extensive resources. Discuss with your mental health provider as part of treatment planning.